C-reactive protein in peripheral arterial disease: Relation to severity of the disease and to future cardiovascular events  by Vainas, Tryfon et al.
C-reactive protein in peripheral arterial disease:
Relation to severity of the disease and to future
cardiovascular events
Tryfon Vainas, MD,a,b Frank R. M. Stassen, PhD,b,c Rick de Graaf, MD,a,b Eric L. L. Twiss, MD,a,b
Selma B. Herngreen, BSc,b,c Rob J. Th. J. Welten, MD, PhD,d Luc H. J. M. van den Akker, MD,e
Marja P. van Dieijen-Visser, PhD,b,f Cathrien A. Bruggeman, PhD,b,c and
Peter J. E. H. M. Kitslaar, MD, PhD,a,b Maastricht, The Netherlands
Background: Serum C-reactive protein (CRP) has proven to be an independent marker of the extent of atherosclerosis in
patients with coronary, cerebrovascular, and peripheral arterial disease. In this prospective observational study, we
wanted to assess the relationship between serumCRP and extent of disease transversely and longitudinally in time, as well
as future cardiovascular complications in patients with peripheral arterial disease (PAD). Hypothesizing that CRP not
only is a marker of but also actively participates in atherogenesis, we explored the possibility of CRP production by
femoral atherosclerotic plaques.
Methods: Serum CRP was measured as highly sensitive (hsCRP) in 387 patients with PAD attending the vascular clinic of
a university and 2 affiliated teaching hospitals. Serum hsCRP was related to the ankle-brachial pressure index (ABPI) as
an indication of severity of disease at inclusion and at 12 months’ follow-up and to future events (death and coronary,
cerebral, and peripheral arterial events). In femoral plaques, the production of CRP was analyzed with reverse
transcription-polymerase chain reaction, and CRP plaque localization was assessed with immunostaining on serial tissue
sections with antibodies toward CRP, smooth muscle cells, T cells, and macrophages.
Results: The hsCRP (average  SD) was 3.26  2.41 mg/L. Serum hsCRP showed a correlation with baseline and
12-month follow-up ABPI (Spearman rank correlation; P < .05 for both correlations). When the patients were divided
into three equally sized groups according to baseline serum hsCRP, the ABPI at baseline and at 12 months decreased
significantly from the low- to the high-hsCRP group (baseline ABPI: 0.70, 0.65, and 0.57, P< .01; 12-month follow-up
ABPI: 0.78, 0.70, and 0.65, P < .01). These associations persisted after correction for conventional risk factors.
Furthermore, serum hsCRP was related to the combined end point “death and/or any cardiovascular event” (log-rank
test; P  .04) during a median 24-month follow-up period. Reverse transcription-polymerase chain reaction analysis
showed CRP production in 4 of 14 femoral plaques. CRP was detected in all femoral plaques, but not in healthy brachial
arteries. Immunoreactivity for CRP was observed in smooth muscle cells, macrophages, and T cells.
Conclusions: Serum hsCRP was related to the severity of PAD, showing a relation to future hemodynamic function and
cardiovascular events in PAD patients. In addition to coronary plaques, aneurysmal aortas, and failed venous coronary
bypasses, femoral plaques also produce CRP, thus illustrating that the production of CRP may represent a universal
response to vascular injury and suggesting that vascular CRPmay contribute to plaque development. (J Vasc Surg 2005;
42:243-51.)In concord with the inflammatory nature of atheroscle-
rosis, several inflammatory markers, such as white blood
cell count,1 erythrocyte sedimentation rate,2 and C-
reactive protein (CRP) have been associated with coronary
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doi:10.1016/j.jvs.2005.03.060artery disease. Of these, CRP is themost extensively studied
in this regard. It has been shown that serum CRP is
increased in patients with coronary artery disease,3 whereas
in healthy middle-aged and elderly individuals, it is associ-
ated with the development of coronary,4,5 cerebral,5,6 and
peripheral7 vascular events.
Peripheral arterial disease (PAD) is a common manifes-
tation of atherosclerosis. Its estimated prevalence varies
between 0.6% and 8.8%.8 Compared with healthy controls,
patients with PAD have increased serum CRP levels.9,10
Furthermore, serumCRP seems to be associated with a low
ankle-brachial pressure index (ABPI 0.9),10 walking per-
formance,11 and endothelial function in these patients.9
Nevertheless, it remains to be seen whether serum CRP is
longitudinally related in time to the severity of PAD and
whether it is related to future cardiovascular complications
in patients with PAD.
The relationship between CRP and the extent of ath-
erosclerosis does not necessarily reflect the systemic nature
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erosclerosis that leads to stimulated hepatic CRP produc-
tion. In fact, it has been shown that coronary plaques,
aneurysmal aortas, and failed venous bypass grafts produce
CRP.12-14 It remains to be established whether local pro-
duction of CRP is a generalized phenomenon of all vascular
territories affected by atherosclerosis.
In this study, we studied the relationship between
serum CRP and the extent and progression of peripheral
atherosclerotic disease, as well as the development of car-
diovascular complications, in patients with PAD. We also
assessed the possible production of CRP by atherosclerotic
plaques of lower limb arteries.
MATERIALS AND METHODS
Patients. The PAD patients studied were participants
in an antibiotic intervention trial. The trial design and
results have been published previously.15 In short, 509
patients with symptomatic PAD with no recent (6
months) vascular events or interventions, recent (3
months) antibiotic use, renal or liver failure, inflammatory
comorbidity, or malignancy were recruited and treated
with azithromycin (500 mg once daily) or placebo for 3
days. Although baseline Chlamydia pneumoniae seroposi-
tivity was related to future events, azithromycin had no
effect on cardiovascular events during follow-up or on
(changes in) ABPI. Of these patients, 456 patients who had
been entered more than 12 months previously in the trial
were considered for this study. Patients with a suspected
acute phase reaction (CRP 10 mg/L) were not included
(n  69),16 leaving 387 patients for this analysis. In this
patient group, C pneumoniae titers were not related to
serum highly sensitive CRP (hsCRP; Spearman   0.09;
P  .07).
The study was approved by the medical ethics commit-
tees of all participating centers and conformed with the
principles outlined in the Declaration of Helsinki.17 All
patients gave written informed consent.
Assessment of ABPI. The ABPI was measured in the
supine position after a 15-minute rest period. At inclusion,
the ankle pressure was measured in both the posterior tibial
artery and the dorsal pedal artery of the (most) symptom-
atic leg. The highest ankle pressure was used to determine
the ABPI. At follow-up visits, the blood pressure in the
same crural artery was used to determine the follow-up
ABPI.
Risk factor profile. At inclusion, the presence of clas-
sic atherosclerotic risk factors was assessed, ie, smoking
(currently smoking or stopped 10 years ago), diabetes
(currently taking antiglycemic medication or insulin or
fasting blood glucose level 7 mmol/L), hypertension
(currently taking antihypertensive medication or systolic
blood pressure 160 mm Hg), dyslipidemia (currently
taking antilipidemic medication or fasting cholesterol 5
mmol/L), and family history (first-degree relative with
ischemic cardiovascular disease before the age of 70 years).
Follow-up and cardiovascular events. All patients
were followed up semiannually for a variable time period,but minimally for 1 year. The median follow-up was 24
months and ranged from 12 to 48 months.
The primary end point was the combined variable
“all-cause mortality and/or any cardiovascular event.” Car-
diovascular end points have been described elsewhere.15
Briefly, coronary events included myocardial infarction, de
novo unstable angina pectoris, and any coronary revascu-
larization procedure. A cerebral event was any stroke or
transient ischemic attack. A peripheral arterial event was
defined as any increase in peripheral ischemic symptoms (ie,
ischemic pain) that was accompanied either by a significant
decrease in ABPI (ie, [ABPI] 0.1) or by any peripheral
revascularization procedure (percutaneous transluminal
angioplasty or operation). Tominimize the risk of scoring a
revascularization as an event soon after inclusion in the
study even though no actual progression in atherosclerotic
disease had occurred, patients were admitted to the study
only after a definitive inclusion vascular treatment plan had
been designed for each patient (conservative vs angioplasty
vs surgery). Only revascularization procedures that devel-
oped beyond this inclusion treatment plan were scored as
events.
SerumCRP level. Venous blood was obtained during
baseline assessment. To obtain serum, blood was immedi-
ately centrifuged at 1200 rpm at 4°C for 10 minutes, and
the serum was stored at 20°C until analysis.
CRP was determined hsCRP with the Immulite assay
(Diagnostic Products Corporation Nederland BV, Breda,
The Netherlands). It provides a detection limit of 0.10
mg/L (zero calibrator  2 SD) and a measurable range of
0.1 to 500mg/L (manufacturer’s claim). The coefficient of
variation of this assay depends on the average hsCRP values,
and at our laboratory it varied from 2.1% to 6.7%.18 This
assay thus provides adequate precision for cardiovascular
risk stratification,19 and it has been approved by the Food
and Drug Administration for clinical use in the United
States.
Atherosclerotic vascular tissue. Femoral endarter-
ectomy specimens from 34 patients who underwent op-
eration consecutively at our clinic were collected. Of
these, 12 patients participated in the prospective, sero-
logic part of the study. Femoral plaques used for reverse
transcription-polymerase chain reaction (RT-PCR; n 
14) were snap-frozen in liquid nitrogen and stored at
80°C until analysis. Plaques for immunohistochemical
analysis (n  20) were formalin-fixed and paraffin-
embedded.
CRP RT-PCR and immunohistochemical analysis.
The presence of messenger RNA points to active transcrip-
tion of a gene, thus implicating synthesis of the gene
product. To assess whether CRP was produced in femoral
atherosclerotic plaques, the presence of CRP messenger
RNA was determined in this tissue by RT-PCR as previ-
ously described.13
The presence and localization of CRP in atherosclerotic
plaques of femoral arteries was further assessed immunohis-
tochemically. To identify CRP-positive cells, smooth mus-
cle cells, T cells, and macrophages were stained immuno-
sulin.
of 70
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 2 Vainas et al 245histochemically on serial tissue sections. Femoral
atherosclerotic plaques (n  20) were formalin-fixed and
embedded in paraffin. Serial 4-m sections were deparaf-
finized and incubated with a monoclonal antibody directed
against CRP, an 	-actin smooth muscle cell antibody, a
CD3 (T-cell) antibody, and a CD68 (macrophage) anti-
body (all fromDAKO, Glostrup, Denmark). Subsequently,
incubation with a rabbit anti-mouse antibody (DAKO) and
Table I. Patient characteristics
Variable All patients
n 387
Age, y, mean (SD) 65 (9.5)
Male:female 264:123
Smoking,* n (%) 297 (77)
Dyslipidemia,† n (%) 321 (83)
Hypertension,‡ n (%) 221 (57)
Diabetes,§ n (%) 105 (27)
Positive family history,¶ n (%) 239 (62)
Diagnosis, n (%)
Claudication 351 (91)
Critical limb ischemia 36 (9)
Treatment, n (%)
Conservative 273 (70)
Angioplasty 73 (19)
Surgery 41 (11)
Vascular comorbidity, n (%)
CAD 125 (32)
CVD 62 (16)
AAA 37 (10)
Medication, n (%)
Acetylsalicylic acid 362 (93)
Coumarin 42 (11)
-Blocker 121 (31)
RAS inhibitor 129 (33)
Calcium channel blocker 110 (28)
Statin 321 (83)
CRP, C-reactive protein; CAD, coronary artery disease; CVD, cerebrovascu
*Currently smoking or stopped less than 10 years ago.
†Fasting cholesterol level 5.1 mmol/L, triglyceride level 1.95 mmol/L
‡Systolic blood pressure 160 mm Hg, diastolic blood pressure 95 mm H
§Fasting glucose level 7 mmol/L or use of antiglycemic medication or in
¶First-degree relative with first ischemic cardiovascular event before the age
Table II. ABPI at inclusion and after 12 months’ follow-
up in the entire PAD patient population and in the
subgroups of patients with or without an intervention
within 1 year after inclusion
Variable
Entire
population
(n  387)
Patients
without
intervention
(n  259)
Patients
undergoing
intervention
(n  128)
ABPI at inclusion 0.64 (0.18) 0.67 (0.18) 0.59 (0.17)
ABPI at 12 mo 0.72 (0.20) 0.69 (0.18) 0.76 (0.23)
P value (paired-
sample t test) .001 .001 .001
ABPI, Ankle-brachial pressure index; PAD, peripheral arterial disease.
Data are mean (SD) ABPI.streptavidin-biotin complex was performed in a multistepimmunostaining procedure. The coloric reaction was cre-
ated with diaminobenzidine. Two healthy brachial artery
specimens obtained at postmortem examination from fatal
trauma victims were used as negative tissue controls in each
run.
Statistics. SPSS 10.0 for Windows (SPSS Inc, Chi-
cago, Ill) was used for statistical analysis. The 
2 test was
used for comparison of dichotomous/categorical vari-
ables. The Spearman rank correlation was used to ex-
plore the association between serum hsCRP and ABPI at
inclusion and at 12 months. The paired-samples t test
was used for comparison of baseline and 12-month
follow-up ABPI. After the patient population was di-
vided into three equally sized groups according to base-
line serum hsCRP, analysis of variance (ANOVA) with
the Bonferroni correction was used to compare mean
baseline and 12-month follow-up ABPI among the three
groups. Parameters that were significantly associated
with ABPI in the univariate analyses were entered as
potential confounders in a multivariate ANOVA to study
the relationship between ABPI and serum hsCRP.
Kaplan-Meier models with log-rank statistics were con-
structed to compare freedom from clinical end points
among patients in the three CRP groups. Cox propor-
tional hazard models were used to correct for relevant
ow CRP Intermediate CRP High CRP
129 129 129
4 (8.9) 65 (10.4) 66 (8.7)
85:44 88:41 91:38
5 (74) 101 (78) 101 (78)
8 (84) 108 (84) 105 (81)
6 (59) 70 (55) 75 (58)
8 (29) 33 (26) 34 (26)
9 (61) 81 (63) 79 (61)
9 (92) 120 (93) 112 (87)
0 (8) 9 (7) 17 (13)
0 (70) 90 (70) 93 (72)
9 (22) 22 (17) 22 (17)
0 (8) 17 (13) 14 (11)
2 (33) 41 (32) 42 (33)
3 (10) 28 (22) 21 (16)
5 (12) 9 (7) 13 (10)
0 (93) 123 (95) 119 (92)
2 (9) 15 (12) 15 (12)
3 (33) 39 (30) 39 (30)
6 (36) 40 (31) 43 (33)
2 (25) 40 (31) 38 (29)
8 (84) 108 (84) 105 (81)
sease; AAA, abdominal aortic aneurysm; RAS, renin-angiotensin system.
e of antidyslipidemic medication.
the use of antihypertensive medication.
years.L
6
9
10
7
3
7
11
1
9
2
1
4
1
1
12
1
4
4
3
10
lar di
, or us
g, orcovariables.
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Patient characteristics and vascular status are shown in
Table I. The patients analyzed had severe PAD, as revealed
by an average (SD) baseline ABPI at inclusion of 0.64
(0.18) (Table II). After 12 months, the average (SD) ABPI
increased significantly to 0.72 (0.20) (paired-samples t test;
P .001). This increase resulted mainly from interventions
(Table II).
The extent of systemic atherosclerotic disease in these
patients was reflected in the high prevalence of coronary
and cerebrovascular comorbidity (Table I) and in the sig-
nificant number of cardiovascular and cerebrovascular com-
plications and deaths during follow-up. Approximately one
third of the PAD patients had coexisting coronary artery
disease, and 16% had cerebrovascular comorbidities. Dur-
ing a 24-month follow-up period, 136 (35.1%) PAD pa-
tients developed 184 vascular events (coronary, cerebral, or
peripheral) or died. Thirty-two patients died (all-cause
mortality), 29 developed 30 coronary events, 25 patients
experienced 26 transient ischemic attacks or strokes, and 76
had, in total, 96 peripheral arterial events (Table III).
The median (interquartile range) serum hsCRP in PAD
patients was 2.65 mg/L (1.35-4.41 mg/L). Because the
mean hsCRP value (3.26 mg/L) was greater than 3 mg/L,
these patients should be considered as being at high risk for
future complications according to guidelines from the
American Heart Association and the Centers for Disease
Control and Prevention.16
Serum hsCRP was related to severity of PAD. Base-
line serum hsCRP was significantly correlated with the
ABPI at inclusion (Spearman   0.306; P  .01) and
with the ABPI at 12 months (Spearman  0.256; P
.01). When patients were divided into three equally sized
groups according to baseline hsCRP level—ie, low
hsCRP (CRP 1.72 mg/L), intermediated hsCRP (1.72
mg/L  hsCRP 3.56 mg/L), and high hsCRP (hsCRP
3.56 mg/L)—ABPI at inclusion decreased from the
lowest to upper tertile (average baseline ABPI was 0.70,
0.65, and 0.57 in the low-, intermediate-, and high-
hsCRP groups, respectively; ANOVA; P  .001 for the
Table III. Incidence of cardiovascular events in PAD pati
levels
Variable
Total group
(n  387)
Low-CRP group*
(n  129)
Combined end point 136 (35.1) 33
Death 32 (8.2) 6
Coronary end point 29 (7.4) 7
Cerebral end point 25 (6.5) 6
Peripheral end point 76 (19.6) 23
PAD, Peripheral arterial disease; hsCRP, highly sensitive C-reactive protein
Data are numbers (percentages) of patients with an event.
*Low-CRP group (CRP 1.72 mg/L).
†Intermediate-CRP group (1.72 mg/L  hsCRP 3.56 mg/L).
‡High-CRP group (hsCRP 3.56 mg/L).
§Chi-square test for trend.trend; Fig 1, a ). This association persisted after correct-ing for relevant risk factors, ie, diabetes, hypertension,
smoking, age, sex, and critical limb ischemia (multivari-
ate ANOVA; P  .001 for the trend). Intriguingly, the
ABPI at 12 months’ follow-up showed a similar signifi-
cant decrease with baseline serum hsCRP (average 12-
month follow-up ABPI: 0.78, 0.70, and 0.65 in the low-,
intermediate-, and high-hsCRP group, respectively;
ANOVA; P  .001; Fig 1, b ). Again, the association
between baseline hsCRP and ABPI at 12 months per-
sisted after correction for the risk factors mentioned
previously (multivariate ANOVA; P  .001 for the
trend).
Serum hsCRP exhibited a relation with the occurrence
of complications during follow-up. The incidence of all
vascular events increased from the low-hsCRP group to the
high-hsCRP group (Table III). However, only for the
combined end point did this association reach a statistically
significant level (
2 for trend; P  .020). Accordingly, the
freedom from any clinical end point seemed shorter with
higher baseline serum hsCRP. Again, only for the combined
end point of all-cause mortality and/or any cardiovascular
complication did this association reach statistical signifi-
cance (log-rank statistics; P  .036; Fig 2). The significance
of this relation survived correction for conventional cardio-
vascular risk factors and clinical severity of PAD in a Cox
proportional hazards model (P  .003).
Fourteen atherosclerotic femoral plaques from 14
patients undergoing vascular operation of the lower limb
were analyzed by RT-PCR to assess the local production
of CRP in femoral atherosclerotic plaques. Four (29%) of
the 14 plaques showed evidence of CRP messenger RNA
production. The housekeeping gene cyclophilin was de-
tected in all samples (Fig 3). Furthermore, immunohis-
tochemical analysis of 20 femoral atherosclerotic plaques
from 20 consecutive patients and 2 healthy brachial
arteries showed omnipresence of CRP in all plaques and
almost complete absence of CRP in normal arteries (Fig
4). CRP-immunoreactive cells were also positive for
CD3 (T cells), 	-actin (smooth muscle cells), or CD-68
with low, intermediate, or high baseline serum hsCRP
Intermediate-CRP group†
(n  129)
High-CRP group‡
(n  129)
P
value§
51 52 .020
12 14 .170
12 10 .493
7 12 .266
28 25 .733ents
.(macrophages) (Fig 4).
trend
ANO
03).
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In this study, we analyzed the inflammatory profile of
PAD patients and assessed the association between hsCRP
and the extent of atherosclerotic disease in these patients.
Our data showed that PAD patients have increased serum
hsCRP. Furthermore, hsCRP was inversely related to ABPI.
This is in agreement with previous studies that showed that
hsCRP is associated with hemodynamic (eg, ABPI)10 and
functional (eg, outcome of a 6-minute walk)11 outcomes
and with the clinical severity of PAD.20 Previously pub-
Fig 1. a, Relationship between ankle-brachial pressure i
sensitive C-reactive protein (hsCRP) at inclusion. The a
to the high-CRP group (analysis of variance [ANOVA];
also decreased from high to low baseline serum hsCRP (
Fig 2. Difference in freedom from the combined end p
peripheral) among patients with low vs intermediate vs
This association persisted after correction for convention
arterial disease (Cox proportional hazards model; P  .0lished data have shown that preprocedural serum CRP isindependently related to early and late clinical cardiovascu-
lar events and to restenosis after coronary percutaneous
intervention.21,22 Accordingly, our data showed that base-
line serum hsCRP was inversely related to ABPI measured
12 months later. This may suggest that high baseline serum
hsCRP may identify patients who are most likely to develop
restenosis or experience accelerated atherosclerosis of the
native lower limb arteries. Serum hsCRP has been associ-
ated with the development of complications of the coro-
nary, cerebral, and peripheral arterial circulation in appar-
(ABPI; at inclusion and at 12 months) and serum highly
e ABPI at inclusion decreased from the low-CRP group
 .001). b, The average ABPI at 12 months’ follow-up
VA; Ptrend  .001). CI, Confidence interval.
death and/or any vascular event (coronary, cerebral, or
-reactive protein (CRP; log-rank statistics; P  .036).
rdiovascular risk factors and clinical extent of peripheralndex
verag
Point
high C
al caently healthy individuals.4-7 With this prospective study, we
and
JOURNAL OF VASCULAR SURGERY
August 2005248 Vainas et alwere able to demonstrate that serum hsCRPwas also related
to the development of atherosclerosis-related events or
death in PAD patients. To the best of our knowledge, this
is the first study to demonstrate that serum hsCRP is related
to future hemodynamic function and future cardiovascular
events in patients with PAD. Hence, serum hsCRP may be
used to estimate the extent of atherosclerotic disease and
may facilitate cardiovascular risk estimation in PAD patients
and healthy individuals. Additionally, recently published
data have demonstrated that decreasing serum CRP by
statins resulted in a significant reduction of the cardiovas-
cular event rate regardless of the resultant low-density
lipoprotein cholesterol level. Consequently, cardiovascular
risk-reduction strategies involving statins should include
serum CRP monitoring.23
It is believed that cytokine-stimulated production of
CRP by hepatocytes is responsible for the increased CRP
levels in atherosclerosis. Localization of CRP extracellu-
larly and in macrophages shown in human atheroscle-
rotic aortic lesions was thought to result from uptake of
CRP-lipid complexes by macrophages.24 However, re-
cent evidence suggests that diseased vascular tissue can
produce CRP as well. Coronary plaques,12 aneurysmal
aortas,13 and failed venous coronary bypasses14 have
been shown to produce CRP. In this study, we demon-
Fig 3. Representative gel showing C-reactive protein (C
a patient with peripheral arterial disease. Lane 1 cont
Belgium). Lane 2 has been loaded with CRP amplificatio
femoral plaque CRP amplification product without pr
demonstrating the specific amplification of RNA inste
polymerase chain reaction product from femoral plaque,strated that femoral atherosclerotic plaques produceCRP as well. Using immunohistochemical staining on
serial tissue sections, we identified smooth muscle cells,
macrophages, and T cells as the putative cellular produc-
tion sites of CRP. Yasojima et al12 suggested that smooth
muscle–like cells and macrophages produce CRP in cor-
onary atherosclerotic plaque, whereas Kuta and Baum25
and Ikuta et al26 independently showed that lympho-
cytes produce CRP when stimulated with lipopolysac-
charide or 10-O-tetradecanoyl-phorbol-13-acetate, re-
spectively.
Considering the presence and local production of
CRP in atherosclerotic tissue, it is logical to assume that
CRP actively participates in the atherosclerotic process.
Recent evidence suggests that CRP has proatherogenic
effects on all cellular constituents of the vascular wall.
CRP colocalizes with the membrane attack complex in
atherosclerotic plaques and activates complement.12,27
CRP is chemotactic for circulating monocytes,28 stimu-
lates monocyte tissue factor production,29 upregulates
some macrophage proinflammatory cytokines,30 and
causes a sustained increase in native low-density lipopro-
tein uptake by macrophages.31 Through activation of
nuclear factor-B, CRP may induce endothelial adhesion
molecules,32 stimulate endothelial monocyte chemoat-
tractant protein 1 release,33 and inhibit basal and stimu-
messenger RNA in femoral atherosclerotic plaque from
a marker for size (SmartLadder; Eurogentec Seraing,
duct from femoral plaque. Lane 3 has been loaded with
anscription of RNA into complementary DNA (-RT),
genomic DNA. Lane 4 was loaded with cyclophilin
lane 5 was loaded with water.RP)
ains
n pro
ior tr
ad oflated endothelial nitric oxide release.34 Similarly, CRP
ques.
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kin 6, and inducible nitric oxide synthetase expression in
vascular smooth muscle cells.35 Most of the previously
described proinflammatory effects have been demon-
strated in vitro by using CRP concentrations ranging
Fig 4. Immunohistochemical detection of C-reactive pr
healthy brachial artery. CRPwas abundantly present in fem
in healthy tissue (B). CRP immunostaining (C) colocalize
(F) in serial tissue sections of femoral atherosclerotic plafrom 5 to 900 mg/L. Therefore, it has recently beenquestioned whether the plasma concentration of CRP
used to denote a high risk for future cardiovascular
complications (3 mg/L) is able to elicit these proin-
flammatory effects in the vascular wall.36 Local produc-
tion of CRP in the vascular wall as demonstrated in this
(CRP) in femoral atherosclerotic plaques and apparently
atherosclerotic plaque (A) and almost completely absent
h T cells (D), smoothmuscle cells (E), andmacrophagesotein
oral
d witstudy may overcome this problem by yielding high CRP
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sclerotic vessel wall.
The associations described here reflect the inflamma-
tory nature of atherosclerosis. Because chronic infections
have also been associated with atherosclerosis develop-
ment,37 it is very reasonable to suggest that microorgan-
isms may be related to the increased serum CRP levels in
atherosclerotic patients. In our study population, C
pneumoniae serology was not related to the serum CRP
concentration. Furthermore, although both C pneu-
moniae seropositivity and serum CRP had an indepen-
dent effect on cardiovascular events, we were not able to
demonstrate a synergistic effect of these variables on
cardiovascular risk. This may be related to the fact that
only patients with no recent infections or vascular inter-
ventions were analyzed. Additionally, it is more likely
that total pathogen burden, rather than infection with
one microorganism, may be related to CRP levels and
cardiovascular risk.
In conclusion, our data demonstrate that in addition to
being a marker of atherosclerosis, CRP is produced within
the atherosclerotic plaque and may locally participate in
plaque development. Unraveling the parameters that gov-
ern vascular CRP production may offer new ways of inter-
fering with atherogenesis.
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